EULAR definition of difficult-to-treat rheumatoid arthritis

György Nagy(Semmelweis University), Nadia M T Roodenrijs(Utrecht University), Paco M J Welsing(Utrecht University), Melinda Kedves(Bács-Kiskun Megyei Kórház), Attila Hamar(University of Debrecen), Marlies C. van der Goes(Utrecht University), Alison Kent(Salisbury NHS Foundation Trust), Margôt Bakkers(European League Against Rheumatism), Etienne Blaas(Utrecht University), Ladislav Šenolt(Charles University), Zoltán Szekanecz(University of Debrecen), Ernest Choy(CREATe Centre), Maxime Dougados(Inserm), Johannes W. G. Jacobs(Utrecht University), Rinie Geenen(Utrecht University), Hans Bijlsma(Utrecht University), A. Zink(German Rheumatism Research Centre), Daniel Aletaha(Center for Rheumatology), Leonard Schoneveld(Bravis Ziekenhuis), Piet L. C. M. van Riel(Radboud University Nijmegen), Loriane Gutermann(Université Paris Cité), Yeliz Prior(University of Salford), Elena Nikiphorou(King's College London), Gianfranco Ferraccioli(Università Cattolica del Sacro Cuore), Georg Schett(Friedrich-Alexander-Universität Erlangen-Nürnberg), Kimme L Hyrich(Manchester Academic Health Science Centre), Ulf Müeller-Ladner(Justus-Liebig-Universität Gießen), Maya H Buch(University of Leeds), Iain B. McInnes(Institute of Infection and Immunity), Désirée van der Heijde(Leiden University Medical Center), Jacob M. van Laar(Utrecht University)
Annals of the Rheumatic Diseases
October 1, 2020
Cited by 531Open Access
Full Text

Abstract

BACKGROUND: Despite treatment according to the current management recommendations, a significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These patients can be considered to have 'difficult-to-treat RA'. However, uniform terminology and an appropriate definition are lacking. OBJECTIVE: Development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis" aims to create recommendations for this underserved patient group. Herein, we present the definition of difficult-to-treat RA, as the first step. METHODS: The Steering Committee drafted a definition with suggested terminology based on an international survey among rheumatologists. This was discussed and amended by the Task Force, including rheumatologists, nurses, health professionals and patients, at a face-to-face meeting until sufficient agreement was reached (assessed through voting). RESULTS: The following three criteria were agreed by all Task Force members as mandatory elements of the definition of difficult-to-treat RA: (1) Treatment according to European League Against Rheumatism (EULAR) recommendation and failure of ≥2 biological disease-modifying antirheumatic drugs (DMARDs)/targeted synthetic DMARDs (with different mechanisms of action) after failing conventional synthetic DMARD therapy (unless contraindicated); (2) presence of at least one of the following: at least moderate disease activity; signs and/or symptoms suggestive of active disease; inability to taper glucocorticoid treatment; rapid radiographic progression; RA symptoms that are causing a reduction in quality of life; and (3) the management of signs and/or symptoms is perceived as problematic by the rheumatologist and/or the patient. CONCLUSIONS: The proposed EULAR definition for difficult-to-treat RA can be used in clinical practice, clinical trials and can form a basis for future research.


Related Papers

No related papers found

Powered by citation graph analysis